Supplementary Table S2: Ocular (study eye) and nonocular adverse events leading to permanent study treatment discontinuation, regardless of study treatment relationship, by primary system organ class and preferred term (safety set)

Primary system organ class Preferred term, n (%)	T&E ranibizumab 0.5 mg+laser n=126	T&E ranibizumab 0.5 mg n=126	PRN ranibizumab 0.5 mg n=118
Ocular AEs			
Any primary system organ class	1 (0.8)	0 (0.0)	0 (0.0)
Eye disorders	1 (0.8)	0 (0.0)	0 (0.0)
Macular fibrosis	1 (0.8)	0 (0.0)	0 (0.0)
Nonocular AEs			
Any primary system organ class	9 (7.1)	6 (4.8)	5 (4.2)
Cardiac disorders	1 (0.8)	3 (2.4)	0 (0.0)
Acute myocardial infarction	0 (0.0)	1 (0.8)	0 (0.0)
Arrhythmia	0 (0.0)	1 (0.8)	0 (0.0)
Bradycardia	0 (0.0)	1 (0.8)	0 (0.0)
Coronary artery disease	0 (0.0)	1 (0.8)	0 (0.0)
Myocardial infarction	1 (0.8)	1 (0.8)	0 (0.0)
Myocardial ischemia	0 (0.0)	1 (0.8)	0 (0.0)
Metabolism and nutrition disorders	1 (0.8)	0 (0.0)	0 (0.0)
Dehydration	1 (0.8)	0 (0.0)	0 (0.0)
Musculoskeletal and connective tissue disorders	1 (0.8)	0 (0.0)	1 (0.8)
Pain in extremity	0 (0.0)	0 (0.0)	1 (0.8)
Intervertebral disc protrusion	1 (0.8)	0 (0.0)	0 (0.0)
Myalgia	1 (0.8)	0 (0.0)	0 (0.0)
Spinal osteoarthritis	1 (0.8)	0 (0.0)	0 (0.0)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)	2 (1.6)	0 (0.0)	2 (1.7)
Hepatic cancer	0 (0.0)	0 (0.0)	1 (0.8)
Pancreatic carcinoma	0 (0.0)	0 (0.0)	1 (0.8)
Lung adenocarcinoma	1 (0.8)	0 (0.0)	0 (0.0)
Metastases to peritoneum	1 (0.8)	0 (0.0)	0 (0.0)
Nervous system disorders	1 (0.8)	2 (1.6)	1 (0.8)
Cerebrovascular accident	1 (0.8)	1 (0.8)	1 (0.8)
Transient ischemic attack	0 (0.0)	1 (0.8)	0 (0.0)
Renal and urinary disorders	1 (0.8)	0 (0.0)	1 (0.8)
Haematuria	0 (0.0)	0 (0.0)	1 (0.8)
Renal mass	1 (0.8)	0 (0.0)	0 (0.0)
Respiratory, thoracic and mediastinal disorder	1 (0.8)	1 (0.8)	0 (0.0)
Acute respiratory failure	0 (0.0)	1 (0.8)	0 (0.0)
Pulmonary embolism	1 (0.8)	0 (0.0)	0 (0.0)
Vascular disorders	1 (0.8)	0 (0.0)	0 (0.0)
Hypertension	1 (0.8)	0 (0.0)	0 (0.0)

Safety set consisted of all patients who received at least one active application of study treatment and had at least one post-baseline safety assessment
Percentages are based on the number of patients in the Safety set in the specific treatment group
AEs, adverse events; PRN, pro re nata; T&E, treat-and-extend